Literature DB >> 18306019

Malignant hyperthermia susceptibility diagnosed with a family-specific ryanodine receptor gene type 1 mutation.

Takahiro Tanabe1, Makoto Fukusaki, Yoshiaki Terao, Kazunori Yamashita, Koji Sumikawa, Keiko Mukaida, Carlos A Ibarra, Ichizo Nishino.   

Abstract

Malignant hyperthermia (MH) is an autosomal dominant disorder of skeletal muscle calcium regulation, and the rate of calcium-induced calcium release (CICR), determined by using skinned fibers of skeletal muscle, has been employed as a diagnostic test for MH susceptibility in Japan. The ryanodine receptor (RYR1), encoding the major calcium-release channel in skeletal muscle sarcoplasmic reticulum, has been shown to be mutated in a number of MH pedigrees. We experienced the detection of accelerated CICR and/or an RYR1 mutation in a patient with an MH episode and his family. Accelerated CICR and an RYR1 mutation (c.14512C>G, p.L4838V) were found in the patient and his father. The MH-causative mutation (c.14512C>G, p.L4838V) was also found in his brother and his son (resulting in the diagnosis of MH without the CICR test), but the mutation was not found in his mother or two daughters. With the detection of the family-specific mutation in other family members, the diagnosis of MH was made without the invasive CICR test.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18306019     DOI: 10.1007/s00540-007-0575-1

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  11 in total

Review 1.  [Malignant hyperthermia].

Authors:  Osafumi Yuge; Keiko Mukaida
Journal:  Nihon Rinsho       Date:  2002-01

2.  Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia.

Authors:  A Urwyler; T Deufel; T McCarthy; S West
Journal:  Br J Anaesth       Date:  2001-02       Impact factor: 9.166

Review 3.  Ryanodine receptor calcium release channels.

Authors:  Michael Fill; Julio A Copello
Journal:  Physiol Rev       Date:  2002-10       Impact factor: 37.312

4.  Malignant hyperthermia genetic testing in North America Working Group Meeting. Bethesda, Maryland. September 4-5, 2002.

Authors:  Yoshitatsu Sei; Nyamkhishig Sambuughin; Sheila Muldoon
Journal:  Anesthesiology       Date:  2004-02       Impact factor: 7.892

5.  In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.

Authors:  H Ording; V Brancadoro; S Cozzolino; F R Ellis; V Glauber; E F Gonano; P J Halsall; E Hartung; J J Heffron; L Heytens; G Kozak-Ribbens; H Kress; R Krivosic-Horber; F Lehmann-Horn; W Mortier; Y Nivoche; E Ranklev-Twetman; S Sigurdsson; M Snoeck; P Stieglitz; V Tegazzin; A Urwyler; F Wappler
Journal:  Acta Anaesthesiol Scand       Date:  1997-09       Impact factor: 2.105

6.  Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.

Authors:  Carlos A Ibarra M; Shiwen Wu; Kumiko Murayama; Narihiro Minami; Yasuko Ichihara; Hirosato Kikuchi; Satoru Noguchi; Yukiko K Hayashi; Ryoichi Ochiai; Ichizo Nishino
Journal:  Anesthesiology       Date:  2006-06       Impact factor: 7.892

Review 7.  Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders.

Authors:  Susan Treves; Ayuk A Anderson; Sylvie Ducreux; Alexandra Divet; Christophe Bleunven; Cristiano Grasso; Silvia Paesante; Francesco Zorzato
Journal:  Neuromuscul Disord       Date:  2005-10       Impact factor: 4.296

Review 8.  Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group.

Authors:  M G Larach
Journal:  Anesth Analg       Date:  1989-10       Impact factor: 5.108

9.  Novel mutations in C-terminal channel region of the ryanodine receptor in malignant hyperthermia patients.

Authors:  Hideto Oyamada; Keiko Oguchi; Naoto Saitoh; Toshiko Yamazawa; Kenzo Hirose; Yoko Kawana; Kazunao Wakatsuki; Katsuji Oguchi; Megumi Tagami; Kazuo Hanaoka; Makoto Endo; Masamitsu Iino
Journal:  Jpn J Pharmacol       Date:  2002-02

10.  Comparison of the in vitro caffeine-halothane contracture test with the Ca-induced Ca release rate test in patients suspected of having malignant hyperthermia susceptibility.

Authors:  S Oku; K Mukaida; S Nosaka; Y Sai; Y Maehara; O Yuge
Journal:  J Anesth       Date:  2000-01-20       Impact factor: 2.078

View more
  1 in total

1.  Ring fibers visualized by electron microscopy in a Japanese patient with malignant hyperthermia.

Authors:  Yoshimasa Kitagawa; Jun Sato; Masaru Kuriyama; Kazuo Sano; Kenji Hashimoto
Journal:  Odontology       Date:  2011-01-27       Impact factor: 2.634

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.